Status:
UNKNOWN
Botulinum Toxin to Improve Results in Epicanthoplasty
Lead Sponsor:
Shanghai Jiao Tong University School of Medicine
Conditions:
Scar
Intercanthal Distance Ratio
Eligibility:
FEMALE
18-35 years
Phase:
PHASE3
Brief Summary
Medial epicanthal fold is a common skin fold in the inner part of the eye in more than 50% Asia population, giving the illusion of a shorter palpebral fissure length and a wider intercanthal distance....
Eligibility Criteria
Inclusion
- patients with moderate to severe congenital epicanthus.
- patients accept Park Z epicanthoplasty.
- Written informed consent given
Exclusion
- epicanthus caused by trauma, surgical injury.
- patients with both epicanthus and blepharopotosis.
- patients with blepharophimosis-ptosis-epicanthus inversus syndrome, or only inversus epicanthus
- patients underwent Botulinum Toxin Type A periocular injection within 6 months
- patients ever have been allergic to Botulinum Toxin Type A or any components of Botulinum Toxin Type A
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
April 1 2018
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT03294382
Start Date
April 1 2017
End Date
April 1 2018
Last Update
September 27 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ru-Lin Huang
Shanghai, China, 200011